115 μmol/L。其中6例患者內(nèi)生肌酐清除率(Ccr)<50 mL/min,3例未實施給藥劑量及給藥頻次調(diào)整。按照藥物說明書相關(guān)適應(yīng)證及患者臨床病理資料,在2018年132例應(yīng)用美羅培南患者病歷中,不合理應(yīng)用藥物的患者占12.88%(17/132),2019年237例應(yīng)用美羅培南患者病歷中,不合理應(yīng)用藥物的患者占3.80%(9/237)。結(jié)論 通過科研點評與信息化管控可發(fā)現(xiàn)醫(yī)院美羅培南使用存在不合理現(xiàn)象,對患者美羅培南使用情況進(jìn)行分析及點評,有利于規(guī)范美羅培南使用,提高臨床用藥的安全性及合理性。;Objective To analyze the rational use of meropenem based on scientific research review and information management. Methods The medical records of patients with meropenem in Tianjin Beichen Hospital from 2018 to 2019 were retrospectively analyzed, and the drug use, diagnosis and course of treatment, bacteria distribution after microbial culture, and dosage of meropenem in patients with renal insufficiency were analyzed, and the rationality was further evaluated according to the relevant guidelines of special antibacterial drugs. Results Compared with 2018, the total number of meropenem medications increased by 60.17%, the duration of medication increased by 3.28%, the number of consumption increased by 60.17%, the number of hospitalization days increased by 173.78%, and the number of medication days increased by 101.76% in 2019. All patients treated with meropenem were diagnosed with pulmonary infection, sepsis, wound infection, submaxillary lymphadenitis, pancreatitis, acute tonsillitis, sepsis, urinary tract infection, etc. The average treatment course of meropenem was (6.31 ±5.01) d in 2018, and (5.97 ±3.02) d in 2019, which decreased by 5.39% in 2019. In 2018, 115 of the 132 patients treated with meropenem underwent microbial examination, with a detection rate of 87.12%, and a total of 33 bacterial strains were cultured. In 2019, of 237 patients treated with meropenem, 236 were submitted for microbial detection, with a detection rate of 99.58%. A total of 45 strains were cultured. In 2018, 132 patients treated with meropenem underwent renal function tests, and the results showed that serum creatinine (Scr) was < 62 μmol/L in 58 patients, 62-115 μmol/L in 54 patients, and > 115 μmol/L in 20 patients. Among them, 6 patients had endogenous creatinine clearance rate (Ccr) < 50 mL/min, and 3 patients did not adjust dose and frequency of administration. According to the indications and clinicopathological data of the patients, among the 132 cases of meropenem application in 2018, 12.88% (17/132) were found to be irrational use of drugs; among the 237 cases of meropenem application in 2019, 3.80% (9/237) were irrational use of drugs. Conclusion The irrational use of meropenem in hospitals can be found through scientific research review and information control. The analysis and comment on the use of meropenem in patients is conducive to standardize the use of meropenem and improve the safety and rationality of clinical medication."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2022年第37卷第2期 >2022,37(2):403-407. DOI:10.7501/j.issn.1674-5515.2022.02.033
上一篇 | 下一篇

基于科研點評與信息化管控美羅培南合理用藥分析

Analysis of rational drug use of meropenem based on scientific research review and information management

發(fā)布日期:2022-02-25